Please login to the form below
trial failure
This page shows the latest trial failure news and features for those working in and with pharma, biotech and healthcare.
Pfizer abandons antibody for Duchenne
Pfizer abandons antibody for Duchenne. Pfizer has halted development of its Duchenne muscular dystrophy (DMD) candidate domagrozumab on disappointing results in a mid-stage efficacy trial. ... Pfizer started dosing patients with its mini-dystrophin
Latest news
-
CTI slumps as Servier-partnered lymphoma drug fails
CTI BioPharma has been poleaxed by the news that its much-anticipated late-stage trial for Pixuvri in non-Hodgkin’s lymphoma (NHL) has ended in failure. ... The PIX306 trial paired Pixuvri (pixantrone) – already sold in some European markets as a
-
Summit plunges after Duchenne disappointment
Summit plunges after Duchenne disappointment. UK company to abandon lead molecule after phase II trial failure. ... However while this clinical trial failure was once typical of the DMD field, there are signs of a breakthrough against the life-shortening
-
AZ’s Fasenra hit by COPD trial failure
AZ’ s Fasenra hit by COPD trial failure. Results give advantage to respiratory rivals GSK. ... AstraZeneca’s hopes of taking on rival GlaxoSmithKline in the respiratory antibody sector have taken a knock after a failed phase III trial.
-
BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace
The failure of Incyte’s IDO1 inhibitor epacadostat in a trial pairing it with Merck &Co/MSD’s PD-1 inhibitor Keytruda (pembrolizumab) last month seems to have started a chain ... The Incyte trial failure was swiftly followed by a decision by NewLink
-
AZ’s immuno-oncology combo fails another lung cancer trial
AZ’ s immuno-oncology combo fails another lung cancer trial. Latest failure casts doubt on company’s CTLA4 drug. ... achieved a “clinically meaningful reduction in the risk of death compared to chemotherapy”, although the trial wasn’t powered
More from news
Approximately 32 fully matching, plus 59 partially matching documents found.
Latest Intelligence
-
VIDEO interview: Neil Weir, UCB
Avoiding failure. By taking this approach to research, it's possible to avoid one of the major pitfalls facing pharma today – the high cost of late-stage trial failure. “ ... Particularly when we have high failure rates in late stages in clinical
-
Customer valuation in pharma
Multiple studies have pegged the probability of clinical trial success at between 13-20 per cent. ... This estimate has remained constant over decades. Among the major reasons for clinical trial failure are problems that rest squarely in the domain of
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Alzheimer's: the numbers we cannot forget
This is one of the highest clinical trial failure rates in healthcare. ... Failures in these trials have been associated with lack of efficacy, excessive side effects, or challenges in trial execution; leaving patients and HCPs with 5 therapies to choose
-
A forward march for adaptive designs
For example, poor dose selection in phase II is frequently cited as one of the top causes of late-stage clinical trial failure. ... As such, it has prioritised phase II/III adaptive trial designs as well as other types of study.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
- Senior Account Director development role to Business Director, H...
-
Excellent package
-
Senior Medical Writer
-
Great salary and benefits
-
Senior Medical Writer
-
Competitive Salary
-
Account Director
-
£48, 000 - £60, 000
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Senior Account Managers - Oxfordshire
-
Attractive salary and benefits package offered
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
-
Medical/ Scientific Director
-
Salary TBC
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
- Director, Market Access / HEOR - North-West
-
Negotiable
-
Account Manager / Account Director
-
Competative
- Senior Account Executive, London, Medical Communications
-
Excellent package
- Account Manager, Healthcare Public Affairs
-
£32, 000 – £40, 000 benefits
-
New Business Director - PR
-
Competitive Salary and benefits
-
Associate Director
-
£75, 000-90, 000
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
Subscribe to our email news alerts
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- OUTiCO win Best in UK Pharmaceutical Outsourcing award
- The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
- Artificial Intelligence in Healthcare
- Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
- World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
- Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
Quick links
Infographics
